Free Trial
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

Karyopharm Therapeutics logo
$5.92 +1.27 (+27.31%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$5.68 -0.24 (-4.05%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Key Stats

Today's Range
$4.67
$6.90
50-Day Range
$3.77
$5.92
52-Week Range
$3.51
$16.95
Volume
1.62 million shs
Average Volume
148,374 shs
Market Capitalization
$51.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00
Consensus Rating
Moderate Buy

Company Overview

Karyopharm Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

KPTI MarketRank™: 

Karyopharm Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 241st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Karyopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Karyopharm Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Karyopharm Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Karyopharm Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Karyopharm Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Karyopharm Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    26.86% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 2.90%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Karyopharm Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Karyopharm Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.86% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 2.90%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Karyopharm Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,787.00 in company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Karyopharm Therapeutics is held by insiders.

  • Percentage Held by Institutions

    66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Karyopharm Therapeutics' insider trading history.
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

Leerink Partnrs Issues Optimistic Estimate for KPTI Earnings
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.
Karyopharm Therapeutics: Q2 Earnings Snapshot
See More Headlines

KPTI Stock Analysis - Frequently Asked Questions

Karyopharm Therapeutics' stock was trading at $10.1445 on January 1st, 2025. Since then, KPTI shares have decreased by 41.6% and is now trading at $5.92.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its earnings results on Monday, August, 11th. The company reported ($4.32) EPS for the quarter, missing analysts' consensus estimates of ($3.80) by $0.52. The firm earned $37.93 million during the quarter, compared to the consensus estimate of $37.92 million.
Read the conference call transcript
.

Karyopharm Therapeutics's stock reverse split on the morning of Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Karyopharm Therapeutics' top institutional investors include Bank of America Corp DE (1.94%), Geode Capital Management LLC (1.06%), Silverback Asset Management LLC (0.81%) and Bridgeway Capital Management LLC (0.44%). Insiders that own company stock include Richard A Paulson, Reshma Rangwala, Stuart Poulton, Michael Mason, Michael Mano, Sohanya Roshan Cheng, Kristin Abate, Stephen Mitchener and Garen G Bohlin.
View institutional ownership trends
.

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS).

Company Calendar

Last Earnings
8/11/2025
Today
8/16/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KPTI
CIK
1503802
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$10.00
Potential Upside/Downside
+474.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.42 million
Net Margins
-90.02%
Pretax Margin
-90.02%
Return on Equity
N/A
Return on Assets
-84.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.99
Quick Ratio
1.28

Sales & Book Value

Annual Sales
$145.24 million
Price / Sales
0.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($27.55) per share
Price / Book
-0.21

Miscellaneous

Outstanding Shares
8,670,000
Free Float
8,413,000
Market Cap
$51.33 million
Optionable
Optionable
Beta
0.28

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:KPTI) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners